Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.04. | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Units Outstanding & Other Information as at 31 March 2024 | - | ASX | ||
07.03. | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Units Outstanding & Other Information as at 29 Feb 2024 | 1 | ASX | ||
05.03. | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Indicative dividends calendar for 2024 | - | ASX | ||
27.02. | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Product Disclosure Statement | - | ASX | ||
27.02. | G MEDICAL INNOVATIONS HOLDINGS LIMITED: Admission and Commencement of Trading - GMVW | - | ASX | ||
18.12.23 | G Medical Innovations Holdings Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
29.11.23 | G Medical Innovations Holdings Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
11.10.23 | Delisting of Securities of Humanigen, Inc.; Vinco Ventures, Inc.; Liquid Media Group Ltd.; Republic First Bancorp, Inc.; G Medical Innovations Holdings Ltd.; Orbital Infrastructure Group, Inc.; Spark Networks SE; DIRTT Environmental Solutions Ltd.; Chengh | 563 | GlobeNewswire (Europe) | NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Humanigen, Inc. Humanigen, Inc.'s securities were suspended on July 26,... ► Artikel lesen | |
05.09.23 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.09.2023 | 546 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 05.09.2023Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.09.2023ISIN NameIT0005421646 LABOMAR... ► Artikel lesen | |
07.08.23 | G Medical Innovations Holdings Ltd.: G Medical Innovations' CEO Issues Update to Shareholders, August 2023 | 331 | GlobeNewswire (Europe) | Rehovot, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) ("G Medical Innovations" or the "Company"), a global leader in next-generation mobile health (mHealth)... ► Artikel lesen | |
19.05.23 | G Medical Innovations Holdings Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification | 592 | GlobeNewswire (Europe) | Rehovot, Israel, May 19, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company, announced... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TELADOC HEALTH | 11,910 | +0,35 % | Teladoc Health kann Umsatz leicht steigern, Verlust aber erhöht sich | PURCHASE, New York (IT-Times) - Teladoc Health hat seine Ergebnisse für das Auftaktquartal des Geschäftsjahres 2024/2025 veröffentlicht und ein kleines Wachstum verzeichnet. Teladoc Aktie: QuartalsergebnisTeladoc... ► Artikel lesen | |
BICO GROUP | 3,974 | -0,50 % | Schock-News für Bico Group Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
DEXCOM | 119,08 | -0,17 % | Dexcom-Aktie: Kurs klettert leicht (119,3621 €) | Am US-amerikanischen Aktienmarkt liegt der Anteilsschein von Dexcom aktuell im Plus. Der jüngste Kurs betrug 128,51 US-Dollar. Freuen können sich gegenwärtig die Aktionäre von Dexcom: Die Aktie weist... ► Artikel lesen | |
HIMS & HERS HEALTH | 10,480 | +0,19 % | Hims & Hers Health Q1 2024 Earnings Preview | ||
NUGEN MEDICAL DEVICES | 0,066 | -5,44 % | Nugen Medical Devices Inc: Nugen Medical two million shares for debt | ||
PLUS THERAPEUTICS | 1,662 | -1,42 % | Plus Therapeutics Inc.: Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team | The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scientific... ► Artikel lesen | |
INVITAE | 0,110 | 0,00 % | Invitae Corp - 8-K, Current Report | ||
ATOSSA THERAPEUTICS | 1,524 | -1,55 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen | SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced an expanded research agreement with Weill Cornell Medicine to explore... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
SONOMA PHARMACEUTICALS | 0,135 | -7,13 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States | BOULDER, CO / ACCESSWIRE / April 9, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
ORPEA | 13,436 | +0,60 % | ORPEA: emeis Sells a Real-Estate Portfolio in the Netherlands Worth a Total Value of Around €97 Million | Regulatory News:
ORPEA (Paris:ORP):
emeis announces that it has signed an agreement to sell a real estate portfolio of eleven nursing homes in the Netherlands to Bouwinvest for a total deed-in-hand... ► Artikel lesen | |
ASENSUS SURGICAL | 0,231 | +2,31 % | Asensus Surgical, Inc.: Asensus Surgical Announces Sendai Tokushukai Hospital in Japan to Initiate Senhance Surgery Program | ||
INVIVO THERAPEUTICS HOLDINGS | 0,310 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.02.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 23.02.2024.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.02.2024.ISIN NameCA58503M4083 MEDIVOLVE... ► Artikel lesen | |
HEALWELL AI | 1,045 | +0,48 % | WELL Health lanciert die zweite Generation seines KI-gestützten Co-Piloten auf Basis der Technologie von HEALWELL Health AI, der Ärzten die Erkennung von chronischen Erkrankungen erleichtert | - WELL
und HEALWELL AI haben die zweite Generation ihres "WELL AI Decision Support"-Tools ("WAIDS") auf den Markt gebracht, das nun auch ein erweitertes Screening auf chronische Krankheiten... ► Artikel lesen | |
CYTOSORBENTS | 0,750 | -7,18 % | CytoSorbents Reports Fourth Quarter and Full Year 2023 Results | STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory... ► Artikel lesen |